Skip to main
BLLN

Billiontoone Inc (BLLN) Stock Forecast & Price Target

Billiontoone Inc (BLLN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

BillionToOne is a molecular diagnostics company with a strong financial position and a competitive advantage in the genetic testing market due to their proprietary technology and strong reimbursement position. Despite lower Q2 prenatal test revenue, the company has exceeded expectations in oncology revenue and total volumes. With a busy roadmap of upcoming catalysts and recent partnerships and product launches, BLLN is recommended as a Buy.

Bears say

BillionToOne is facing competition from multiple players in both its prenatal testing and oncology diagnostics markets, and while the company has shown strong revenue growth and margin expansion, its reliance on senior management and potential for leadership turnover could present challenges. Additionally, there may be concerns about the company's ability to effectively compete with larger and established players in the market. Overall, there are a number of fundamental risks and uncertainties surrounding BillionToOne's future growth and profitability, which could lead to a negative outlook on its stock.

Billiontoone Inc (BLLN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Billiontoone Inc (BLLN) Forecast

Analysts have given Billiontoone Inc (BLLN) a Buy based on their latest research and market trends.

According to 7 analysts, Billiontoone Inc (BLLN) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $126.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $126.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Billiontoone Inc (BLLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.